Literature DB >> 31738624

Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Lingaku Lee1,2, Tetsuhide Ito3, Robert T Jensen1.   

Abstract

Introduction: Recent advances in diagnostic modalities and therapeutic agents have raised the importance of prognostic factors in predicting overall survival, as well as predictive factors for surgical outcomes, in tailoring therapeutic strategies of patients with pancreatic neuroendocrine neoplasms (panNENs).Areas covered: Numerous recent studies of panNEN patients report the prognostic values of a number of clinically related factors (clinical, laboratory, imaging, treatment-related factors), pathological factors (histological, classification, grading) and molecular factors on long-term survival. In addition, an increasing number of studies showed the usefulness of various factors, specifically biomarkers and molecular makers, in predicting recurrence and mortality related to surgical treatment. Recent findings (from the last 3 years) in each of these areas, as well as recent controversies, are reviewed.Expert commentary: The clinical importance of prognostic and predictive factors for panNENs is markedly increased for both overall outcome and post resection, as a result of recent advances in all aspects of the diagnosis, management and treatment of panNENs. Despite the proven prognostic utility of routinely used tumor grading/classification and staging systems, further studies are required to establish these novel prognostic factors to support their routine clinical use.

Entities:  

Keywords:  Pancreatic neuroendocrine neoplasms; biomarker; molecular marker; pathological factor; prognostic factor; surgical resection

Mesh:

Substances:

Year:  2019        PMID: 31738624      PMCID: PMC6923565          DOI: 10.1080/14737140.2019.1693893

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  335 in total

1.  MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.

Authors:  Helen C Miller; Adam E Frampton; Anna Malczewska; Silvia Ottaviani; Euan A Stronach; Rashpal Flora; Daniel Kaemmerer; Gert Schwach; Roswitha Pfragner; Omar Faiz; Beata Kos-Kudła; George B Hanna; Justin Stebbing; Leandro Castellano; Andrea Frilling
Journal:  Endocr Relat Cancer       Date:  2016-06-27       Impact factor: 5.678

2.  Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.

Authors:  Katelin A Mirkin; Christopher S Hollenbeak; Joyce Wong
Journal:  J Surg Res       Date:  2016-12-29       Impact factor: 2.192

Review 3.  Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases.

Authors:  Jeffrey A Norton
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-08       Impact factor: 3.043

4.  Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Authors:  Wen-Chi Chou; Jen-Shi Chen; Yu-Shin Hung; Jun-Te Hsu; Tse-Ching Chen; Chien-Feng Sun; Chang-Hsien Lu; Tsann-Long Hwang
Journal:  Anticancer Res       Date:  2014-10       Impact factor: 2.480

5.  Serum Elastase 1 Level as a Risk Factor for Postoperative Recurrence in Patients with Well-Differentiated Pancreatic Neuroendocrine Neoplasms.

Authors:  Yoshihide Nanno; Hirochika Toyama; Yoh Zen; Masayuki Akita; Yasuhisa Ando; Takuya Mizumoto; Yuki Ueda; Tetsuo Ajiki; Keiichi Okano; Yasuyuki Suzuki; Takumi Fukumoto
Journal:  Ann Surg Oncol       Date:  2018-07-27       Impact factor: 5.344

6.  Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.

Authors:  N Russolillo; L Vigano'; P Razzore; S Langella; M Motta; F Bertuzzo; M Papotti; A Ferrero
Journal:  Eur J Surg Oncol       Date:  2015-04-03       Impact factor: 4.424

7.  Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately.

Authors:  Tsukasa Yoshida; Susumu Hijioka; Waki Hosoda; Makoto Ueno; Masayuki Furukawa; Noritoshi Kobayashi; Masafumi Ikeda; Tetsuhide Ito; Yuzo Kodama; Chigusa Morizane; Kenji Notohara; Hiroki Taguchi; Masayuki Kitano; Kei Yane; Yoshiaki Tsuchiya; Izumi Komoto; Hiroki Tanaka; Akihito Tsuji; Syunpei Hashigo; Tetsuya Mine; Atsushi Kanno; Go Murohisa; Katsuyuki Miyabe; Tadayuki Takagi; Nobutaka Matayoshi; Masafumi Sakaguchi; Hiroshi Ishii; Yasushi Kojima; Keitaro Matsuo; Hideyuki Yoshitomi; Shoji Nakamori; Hiroaki Yanagimoto; Yasushi Yatabe; Junji Furuse; Nobumasa Mizuno
Journal:  Ann Surg Oncol       Date:  2019-03-12       Impact factor: 5.344

8.  Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study.

Authors:  Sven-Petter Haugvik; Eva Tiensuu Janson; Pia Österlund; Seppo W Langer; Ragnhild Sørum Falk; Knut Jørgen Labori; Lene Weber Vestermark; Henning Grønbæk; Ivar Prydz Gladhaug; Halfdan Sorbye
Journal:  Ann Surg Oncol       Date:  2015-12-17       Impact factor: 5.344

9.  Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.

Authors:  Vincenzo Villani; Krishnan K Mahadevan; Matteo Ligorio; Carlos Fernández-Del Castillo; David T Ting; Francesco Sabbatino; Irene Zhang; Mark Vangel; Soldano Ferrone; Andrew L Warshaw; Keith D Lillemoe; Jennifer Wargo; Vikram Deshpande; Cristina R Ferrone
Journal:  Ann Surg Oncol       Date:  2016-03-28       Impact factor: 5.344

10.  A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands.

Authors:  C G Genc; H J Klümpen; M G H van Oijen; C H J van Eijck; E J M Nieveen van Dijkum
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

View more
  22 in total

Review 1.  Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies.

Authors:  R M Ruggeri; E Benevento; F De Cicco; B Fazzalari; E Guadagno; I Hasballa; M G Tarsitano; A M Isidori; A Colao; A Faggiano
Journal:  J Endocrinol Invest       Date:  2022-08-30       Impact factor: 5.467

2.  The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms.

Authors:  Li Quan; Yongkang Liu; Wenjing Cui; Xinru Wang; Weixiao Zhang; Zhongqiu Wang; Chuangen Guo; Chao Lu; Feixiang Hu; Xiao Chen
Journal:  Lipids Health Dis       Date:  2022-07-16       Impact factor: 4.315

3.  Are We Undertreating Black Patients with Nonfunctional Pancreatic Neuroendocrine Tumors? Critical Analysis of Current Surveillance Guidelines by Race.

Authors:  Rui Zheng-Pywell; Alexandra Lopez-Aguiar; Ryan C Fields; Selwyn Vickers; Clayton Yates; Vikas Dudeja; Herbert Chen; Sushanth Reddy; Shishir K Maithel; J Bart Rose
Journal:  J Am Coll Surg       Date:  2022-04-01       Impact factor: 6.532

Review 4.  Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

Authors:  S M Sadowski; C R C Pieterman; N D Perrier; F Triponez; G D Valk
Journal:  Endocr Relat Cancer       Date:  2020-06       Impact factor: 5.678

5.  Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2020-11-11       Impact factor: 3.889

6.  Prognostic factors of primary neuroendocrine breast cancer: A population-based study.

Authors:  Shu-Tao Ma; Ding-Yuan Wang; Yi-Bing Liu; Hui-Jing Tan; Yue-Yue Ge; Yihebali Chi; Bai-Lin Zhang
Journal:  Cancer Med       Date:  2022-05-02       Impact factor: 4.711

7.  Reconsideration of Clinicopathologic Prognostic Factors in Pancreatic Neuroendocrine Tumors for Better Determination of Adverse Prognosis.

Authors:  Anil Aysal; Cihan Agalar; Tufan Egeli; Tarkan Unek; Ilhan Oztop; Funda Obuz; Ozgul Sagol
Journal:  Endocr Pathol       Date:  2021-07-20       Impact factor: 3.943

Review 8.  Multiple Endocrine Neoplasia Type 1: Latest Insights.

Authors:  Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

9.  A Direct Comparison of Patients With Hereditary and Sporadic Pancreatic Neuroendocrine Tumors: Evaluation of Clinical Course, Prognostic Factors and Genotype-Phenotype Correlations.

Authors:  Przemysław Soczomski; Beata Jurecka-Lubieniecka; Aleksandra Krzywon; Alexander Jorge Cortez; Stanisław Zgliczynski; Natalia Rogozik; Małgorzata Oczko-Wojciechowska; Agnieszka Pawlaczek; Tomasz Bednarczuk; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-28       Impact factor: 5.555

10.  Neuroendocrine tumors in Panama: A nationwide database analysis.

Authors:  Moises Cukier; Ruth Vergara; Jorge D Mendez-Rios; Omar Castillo; Irma Barrera; Eliecer Tello; Olivia El Achtar; Yong Loo; Hector Tapia; Guadalupe Perez; Maximino Peña
Journal:  Mol Clin Oncol       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.